Literature DB >> 26437207

Management of periorbital basal cell carcinoma with orbital invasion.

Michelle T Sun1, Albert Wu1, Edwin Figueira1, Shyamala Huilgol2, Dinesh Selva1.   

Abstract

Basal cell carcinoma (BCC) is the most common eyelid malignancy; however, orbital invasion by periocular BCC is rare, and management remains challenging. Established risk factors for orbital invasion by BCC include male gender, advanced age, medial canthal location, previous recurrences, large tumor size, aggressive histologic subtype and perineural invasion. Management requires a multidisciplinary approach with orbital exenteration remaining the treatment of choice. Globe-sparing treatment may be appropriate in selected patients and radiotherapy and chemotherapy are often used as adjuvant therapies for advanced or inoperable cases, although the evidence remains limited. We aim to summarize the presentation and treatment of BCC with orbital invasion to better guide the management of this complex condition.

Entities:  

Keywords:  basal cell carcinoma; basosquamous basal cell carcinoma; cisplatin-based chemotherapy; exenteration; fixed mass; globe displacement; globe-sparing excision; infiltrative basal cell carcinoma; limited ocular motility; medial canthus; morpheoform/sclerosing basal cell carcinoma; perineural invasion; periocular; radiation therapy; recurrent tumor; vismodegib

Mesh:

Year:  2015        PMID: 26437207     DOI: 10.2217/fon.15.190

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  6 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

Review 2.  Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.

Authors:  Yingyun Shi; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2017-05-08       Impact factor: 4.147

3.  Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: A single-center study and a new dedicated therapeutic protocol.

Authors:  Vincenzo De Giorgi; Luciana Trane; Giulia Pieretti; Nicola Santoro; Flavia Silvestri; Federico Venturi; Federica Scarfì; Vincenza Maio; Giuseppe Spinelli; Silvia Scoccianti; Laura Guerrini; Daniela Massi; Cinzia Mazzini; Laura Doni
Journal:  Dermatol Reports       Date:  2021-08-05

4.  Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.

Authors:  Alon Kahana; Shelby P Unsworth; Christopher A Andrews; May P Chan; Scott C Bresler; Christopher K Bichakjian; Alison B Durham; Hakan Demirci; Victor M Elner; Christine C Nelson; Denise S Kim; Shannon S Joseph; Paul L Swiecicki; Francis P Worden
Journal:  Oncologist       Date:  2021-05-31

5.  Vismodegib and orbital excision for treating locally advanced basal cell carcinoma.

Authors:  Daniel T Hogarty; Nicholas G Dewhurst; Benjamin Burt
Journal:  Int Med Case Rep J       Date:  2018-07-31

6.  Lateral frontal galeal-cutaneous flap for reconstruction after orbital exenteration for advanced periorbital skin cancer

Authors:  Predrag Kovacevic; Jasmina Djordjevic-Jocic; Milan Radojkovic
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.